Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AstraZeneca","sponsor":"Circassia Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Circassia To Terminate AstraZeneca Deal And Transfer Assets","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"AstraZeneca to Transfer Global Rights For Eklira and Duaklir to Covis Pharma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Covis Pharma","pharmaFlowCategory":"D","amount":"$270.0 million","upfrontCash":"Undisclosed","newsHeadline":"Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Covis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"LUXEMBOURG","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Aclidinium Bromide

    Menu

    Aclidinium Bromide

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Covis Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Luxembourg
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Covis Pharma Announces Positive Topline Results from the AVANT Phase 3 Clinical Trial Showing Significant Improvement in Patients with Moderate to Severe Stable COPD

              Details:

              Duaklir (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) are inhaled respiratory medicines used for the maintenance treatment of COPD. Eklira is a LAMA and Duaklir is a combination therapy that contains both a LAMA and a long-acting beta2-agonist (LABA).

              Lead Product(s): Aclidinium Bromide,Formoterol Fumarate

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Duaklir

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AstraZeneca

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Covis Completes Acquisition of Global Respiratory Portfolio of Two Medicines from AstraZeneca

              Details:

              Under the terms of the Acquisition agreement, Covis Pharma has completed the acquisition of Eklira® (aclidinium bromide), known as Tudorza® in US and marketed as Bretaris® in some countries, and Duaklir® (aclidinium bromide/formoterol), marketed as Brimica®, from AstraZeneca.

              Lead Product(s): Aclidinium Bromide

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Eklira

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Covis Pharma

              Deal Size: $270.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition January 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AstraZeneca

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              AstraZeneca to Transfer Global Rights For Eklira and Duaklir to Covis Pharma

              Details:

              Covis Pharma acquired the rights of Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol), inhaled respiratory medicines used for the maintenance treatment of COPD from AstraZeneca.

              Lead Product(s): Aclidinium Bromide

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Eklira

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Covis Pharma

              Deal Size: $270.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement November 01, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              AstraZeneca

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Circassia To Terminate AstraZeneca Deal And Transfer Assets

              Details:

              On completion of the Transaction, AstraZeneca will acquire the U.S. commercial rights to Tudorza® and Duaklir® together with certain ancillary rights and assets, from Circassia.

              Lead Product(s): Aclidinium Bromide

              Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Circassia Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Termination April 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              inke Aclidinium Bromide
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Close
              4
              Post Enquiry
              POST ENQUIRY